As a potential target drug for effective cancer treatment, Apo2L/TNF-related apoptosis-inducing ligand (Apo2L/TRAIL), a cytokine in the TNF superfamily, has the ability to selectively induce tumor apoptosis [15]. This evidence concerns the gene TNFSF10 and neoplasm.